Results 111 to 120 of about 416,692 (196)

Gut bacteria-derived sphingolipids alter innate immune responses to oral cholera vaccine antigens. [PDF]

Nat Commun
Chac D, Heller FJ, Banna HA, Kaisar MH, Markiewicz SM, Pruitt EL, Chowdhury F, Bhuiyan TR, Akter A, Khan AI, Dumayas MG, Rice A, Karmakar PC, Dash P, LaRocque RC, Ryan ET, Xu L, Minot SS, Harris JB, Qadri F, Weil AA.   +20 more
europepmc   +1 more source

Comparison of O-specific polysaccharide responses in patients following infection with Vibrio cholerae O139 versus vaccination with a bivalent (O1/O139) oral killed cholera vaccine in Bangladesh. [PDF]

mSphere, 2023
Kaisar MH, Kelly M, Kamruzzaman M, Bhuiyan TR, Chowdhury F, Khan AI, LaRocque RC, Calderwood SB, Harris JB, Charles RC, Čížová A, Mečárová J, Korcová J, Bystrický S, Kováč P, Xu P, Qadri F, Ryan ET.   +17 more
europepmc   +1 more source

Oral cholera vaccine uptake, acceptance and confidence among residents of a high-risk township in Zambia: key insights for future vaccination programs. [PDF]

Int Health
Miti E, Mukosha M, Mwaba J, Mulavu M, Meyer JC, Mudenda S, Godman B, Mwila C, Hamachila A, Kalungia AC.   +9 more
europepmc   +1 more source

A scoping review of facilitators and barriers influencing the implementation of surveillance and oral cholera vaccine interventions for cholera control in lower- and middle-income countries. [PDF]

BMC Public Health, 2023
Trolle H, Forsberg B, King C, Akande O, Ayres S, Alfvén T, Elimian K.   +6 more
europepmc   +1 more source

Optimizing one-dose and two-dose cholera vaccine allocation in outbreak settings: A modeling study. [PDF]

PLoS Negl Trop Dis, 2022
Leung T, Eaton J, Matrajt L.
europepmc   +1 more source

Real-world effectiveness of oral cholera vaccine amid fragility: A case-control study from Eastern Sudan, 2024. [PDF]

IJID Reg
Izzoddeen A, Abolgassim A, Yousif W, Elhussein EA, ElBushra E, Eltayeb D, Elhassan MMO, El-Bushra H.   +7 more
europepmc   +1 more source

Serological responses to killed oral cholera vaccine (OCV) when given 4 years after initial receipt of OCV in Cameroon: A randomized controlled trial. [PDF]

PLOS Glob Public Health
Ateudjieu J, Tchio-Nighie KH, Guenou E, Fokou C, Buh Nkum C, Beyala Bita'a L, Ateudjieu-Kenfack WD, Nanfak S, Debes AK, Sack DA.   +9 more
europepmc   +1 more source

Live, Genetically Attenuated, Cold-Chain-Free Cholera Vaccine-A Research and Development Journey: Light at the End of a Long Tunnel. [PDF]

Malays J Med Sci, 2022
Ravichandran M, Tew HX, Prabhakaran G, Parasuraman S, Norazmi MN.   +4 more
europepmc   +1 more source

Immunogenicity and waning immunity from the oral cholera vaccine (Shanchol™) in adults residing in Lukanga Swamps of Zambia. [PDF]

PLoS One, 2022
Ng Ombe H, Simuyandi M, Mwaba J, Luchen CC, Alabi P, Chilyabanyama ON, Mubanga C, Hatyoka LM, Muchimba M, Bosomprah S, Chilengi R, Kwenda G, Chisenga CC.   +12 more
europepmc   +1 more source

Descriptive analysis of adverse events following immunization with oral cholera vaccine in Lebanon. [PDF]

Front Public Health
Zeitoun A, Ibrahim A, Reda El Sayed S, Hobeika E, Karam R.   +4 more
europepmc   +1 more source